2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow Rezolute: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME) Experimental: Group 1 - 50mg RZ402, Experimental: Group 2 - 200mg RZ402, Experimental: Group 3 - 400mg RZ402 - Diabetic Macular Edema | Phase 2 | Completed | Rezolute | 94 | 2023-02-06 | 2026-09-01 |
| An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism RZ358 Sequential Group Cohort 1, RZ358 Sequential Group Cohort 2, RZ358 Sequential Group Cohort 3 - Congenital Hyperinsulinism | Phase 2 | Completed | Rezolute | 23 | 2020-02-24 | 2025-05-28 |
Congenital Hyperinsulinism (1) · Diabetes Mellitus (1) · Diabetic Retinopathy (1) · Digestive System Diseases (1) · Glucose Metabolism Disorders (1) · Hyperinsulinism (1) · Hypoglycemia (1) · Metabolic Diseases (1) · Pancreatic Diseases (1)
United States (2) · Bulgaria (1) · Canada (1) · Denmark (1) · Georgia (1) · Germany (1) · Israel (1) · Russia (1) · Spain (1) · Turkey (Türkiye) (1) · United Kingdom (1)